News and Announcements
OpenDNA Launches New Tool from AI System
- Published October 03, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
KEY TAKEAWAYS:
- OpenDNA Ltd (ASX: OPN) has launched it’s newest product, Synapse, utilising its AI systems.
- The tool will allow customers with a deeper insight into the interests and psychographics of their users.
- This will provide OpenDNA customers business-ready tools and actionable data.
Highly experienced developer and fund manager, OpenDNA Ltd (ASX: OPN) has launched it’s newest tool, Synapse, a suite of business tools to allow customers a thorough understanding of their users’ interests and psychographics.
Consumers utilizing Synapse can more effectively hit, retain, and convert users of their services. Depending on the business team concentrating on acquiring new users, upselling existing buyers, or effortlessly deepening engagement of content consumers, Synapse renders concise tools to elevate their specific metrics.
OpenDNA’s CEO and MD had informed the ASX that “the release of Synapse enables the power of the OpenDNA AIS platform to grow exponentially, by giving our customers new and robust ways of looking and acting on the data and insights that the platform provides. We are continually exploring ways to leverage our AI technology and to deliver relevant, practical outcomes for customers which improve the already-compelling business proposition that our personalisation technology provides. We understand our customers’ requirements for business-ready tools and actionable data – not just data for data’s sake – and Synapse comprehensively addresses those requirements.”
About OpenDNA Ltd (ASX: OPN)
To businesses, OpenDNA provides real-time insights into their individual customers’ behaviour which allows them to better predict their needs. This enables businesses to deliver a more relevant customer experience at an individual level, which drives increased revenue. OpenDNA’s artificial intelligence and machine-learning system automatically creates detailed psychographic user profiles, which helps deliver better business outcomes.
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
